N
CNMD icon

Natixis’s CONMED CNMD Stock Holding History

Natixis’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,334
Closed -$2.14M – 1055
2025
Q1 		$2.14M Sell
35,334
-78,666
-69% -$5.07M 0.01% 420
2024
Q4 		$7.8M Buy
114,000
+104,250
+1,069% +$7.27M 0.05% 278
2024
Q3 		$701K Buy
+9,750
New +$688K ﹤0.01% 584
2024
Q1 		– Sell
-58,700
Closed -$6.43M – 1035
2023
Q4 		$6.43M Buy
58,700
+3,900
+7% +$403K 0.05% 275
2023
Q3 		$5.53M Buy
54,800
+34,858
+175% +$4.01M 0.04% 280
2023
Q2 		$2.71M Buy
+19,942
New +$2.43M 0.02% 379
2022
Q4 		– Sell
-102,750
Closed -$8.24M – 1132
2022
Q3 		$8.24M Buy
+102,750
New +$9.69M 0.04% 303
2017
Q4 		– Sell
-4,187
Closed -$220K – 891
2017
Q3 		$220K Buy
+4,187
New +$210K ﹤0.01% 1080

Other funds holding CNMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Natixis's CNMD Position: Q2 2025 in Review

Natixis sold out of CONMED (CNMD) in Q2 2025, closing a stake of 35,334 shares — an estimated $2.14M sold.

Natixis first reported a position in CNMD in Q3 2017 and held it in 8 quarters. The position peaked at $8.24M in Q3 2022. 276 funds tracked by Wall St. Rank hold CNMD as of Q2 2025.

  • Natixis reported no remaining CONMED position as of Q2 2025 after selling out during the quarter.
  • Natixis sold 35,334 CONMED shares in Q2 2025, an estimated $2.14M.
  • Natixis first reported a position in CONMED in Q3 2017 and held it in 8 quarters.
  • Natixis's CONMED position peaked at $8.24M in Q3 2022.
  • 276 funds tracked by Wall St. Rank held CONMED as of Q2 2025.

Based on Natixis's 13F filing for Q2 2025, filed 13 Aug 2025.